Androgen Deprivation Therapy and Cardiovascular Disease: What is the Linking Mechanism?

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2016 Apr 2

PMID 27034724

Citations 29

Authors

Piotr Zareba

Wilhelmina Duivenvoorden

Darryl P Leong

Jehonathan H Pinthus

Affiliations

Soon will be listed here.

Abstract

The past decade has brought increased awareness of the potential adverse effects of androgen deprivation therapy (ADT) in men with prostate cancer. Arguably the most important and controversial of these is the increased risk of cardiovascular morbidity and mortality. Although multiple observational studies have shown that men treated with ADT are at increased risk of developing atherosclerotic cardiovascular disease, our understanding of the biological mechanisms that might underlie this phenomenon is still evolving. In this review, we discuss some of the mechanisms that have been proposed to date, including ADT-induced metabolic changes that promote the development and progression of atherosclerotic plaques as well as direct local effects of hormonal factors on plaque growth, rupture and thrombosis.

Citing Articles

Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.

Beitzen-Heineke A, Wise D, Berger J Cardiooncology. 2024; 10(1):87.

PMID: 39639392 PMC: 11619638. DOI: 10.1186/s40959-024-00278-2.

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Reiss A, Vasalani S, Albert J, Drewes W, Li K, Srivastava A Medicina (Kaunas). 2024; 60(11).

PMID: 39596912 PMC: 11596556. DOI: 10.3390/medicina60111727.

Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.

Moryousef J, Duivenvoorden W, Leong D, Pinthus J Prostate Cancer Prostatic Dis. 2024; .

PMID: 39506079 DOI: 10.1038/s41391-024-00897-x.

[Urogeriatric thinking using the example of antiandrogen therapy for prostate cancer].

Wiedemann A, Manseck A, Stein J, Frohner M, Fiebig C, Piotrowski A Urologie. 2024; 63(9):867-877.

PMID: 39110185 DOI: 10.1007/s00120-024-02397-1.

Cardio-oncology in advanced prostate cancer.

Chen K, Wong T, Tan Y, Tay K, Tan W, Chan J Front Oncol. 2024; 14:1386597.

PMID: 38947889 PMC: 11211357. DOI: 10.3389/fonc.2024.1386597.

References

Morote J, Gomez-Caamano A, Alvarez-Ossorio J, Pesqueira D, Tabernero A, Gomez Veiga F . The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol. 2014; 193(6):1963-9. DOI: 10.1016/j.juro.2014.12.086. View

Moorjani S, Dupont A, Labrie F, Lupien P, Brun D, Gagne C . Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987; 36(3):244-50. DOI: 10.1016/0026-0495(87)90183-1. View

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M . Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2014; 68(3):386-96. DOI: 10.1016/j.eururo.2014.11.039. View

Shah P, Falk E, Badimon J, Fernandez-Ortiz A, Mailhac A, Fallon J . Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995; 92(6):1565-9. View

Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat S . Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2014; 13(3):e123-30. DOI: 10.1016/j.clgc.2014.12.003. View

Nettleship J, Jones T, Channer K, Jones R . Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007; 116(21):2427-34. DOI: 10.1161/CIRCULATIONAHA.107.708768. View

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

Nguyen P, Jarolim P, Basaria S, Zuflacht J, Milian J, Kadivar S . Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. J Am Heart Assoc. 2015; 4(4). PMC: 4579953. DOI: 10.1161/JAHA.115.001914. View

Smith J, Bennett S, Evans L, Kynaston H, Parmar M, Mason M . The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001; 86(9):4261-7. DOI: 10.1210/jcem.86.9.7851. View

10.

Muller M, van den Beld A, Bots M, Grobbee D, Lamberts S, van der Schouw Y . Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004; 109(17):2074-9. DOI: 10.1161/01.CIR.0000125854.51637.06. View

11.

Chen H, Jeung E, Stephenson M, Leung P . Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999; 84(2):743-50. DOI: 10.1210/jcem.84.2.5440. View

12.

Oloyo A, Sofola O, Nair R, Harikrishnan V, Fernandez A . Testosterone relaxes abdominal aorta in male Sprague-Dawley rats by opening potassium (K(+)) channel and blockade of calcium (Ca(2+)) channel. Pathophysiology. 2011; 18(3):247-53. DOI: 10.1016/j.pathophys.2011.02.004. View

13.

Liu X, Chan H, Ding G, Cai J, Song Y, Wang T . FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway. Aging Cell. 2015; 14(3):409-20. PMC: 4406670. DOI: 10.1111/acel.12331. View

14.

Goldberg R, Rabin D, Alexander A, Doelle G, Getz G . Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab. 1985; 60(1):203-7. DOI: 10.1210/jcem-60-1-203. View

15.

Basseri S, Lhotak S, Fullerton M, Palanivel R, Jiang H, Lynn E . Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis. Diabetes. 2012; 62(1):158-69. PMC: 3526025. DOI: 10.2337/db12-0256. View

16.

Shahinian V, Kuo Y, Gilbert S . Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010; 363(19):1822-32. DOI: 10.1056/NEJMsa0910784. View

17.

Falk E, Nakano M, Bentzon J, Finn A, Virmani R . Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2012; 34(10):719-28. DOI: 10.1093/eurheartj/ehs411. View

18.

Mukherjee T, Dinh H, Chaudhuri G, Nathan L . Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci U S A. 2002; 99(6):4055-60. PMC: 122647. DOI: 10.1073/pnas.052703199. View

19.

Kane C, Bassett W, Sadetsky N, Silva S, Wallace K, Pasta D . Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005; 173(3):732-6. DOI: 10.1097/01.ju.0000152408.25738.23. View

20.

Campelo A, Cutini P, Massheimer V . Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012; 213(1):77-87. DOI: 10.1530/JOE-11-0441. View